Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Director/PCA Dealing

10 Nov 2023 13:22

RNS Number : 1305T
Allergy Therapeutics PLC
10 November 2023

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

SkyGem Acquisition Limited

2

Reason for the notification

a)

Position / status

Person Closely Associated with Mr. Zheqing (Simon) Shen, Non-Executive Director of Allergy Therapeutics Plc

b)

Initial notification / amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Allergy Therapeutics plc

b)

LEI

213800PQ7AHK7KGVOE23

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of Β£0.001 each

ISIN: GB00B02LCQ05

b)

Nature of the transaction

Acquisition of Ordinary Shares pursuant to the mandatory offer

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Β£0.01

247,935,057

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

9 November 2023

f)

Place of the transaction

Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBMBJTMTBBBLJ
Date   Source Headline
26th Sep 201611:59 amRNSDirector/PDMR Shareholding
26th Sep 201610:46 amRNSHardman Research: Performance drives market share
26th Sep 20167:00 amRNSAllergy Therapeutics Preliminary Results
20th Sep 20164:58 pmRNSIssue of equity in respect of exercise of options
5th Sep 20167:00 amRNSNotice of Preliminary Results
13th Jul 20167:00 amRNSTrading Update
8th Jul 20167:00 amRNSResults of mite immunotherapy Acarovac PlusT
27th Jun 20167:00 amRNSFindings from mEEC dose range finding study G204
13th Jun 20167:00 amRNSAllergy hosts Satellite Symposium at EAACI
10th Jun 20167:00 amRNSAppointment of Finance Director
9th May 20167:00 amRNSPositive Phase II Data
23rd Mar 20169:02 amRNSIssue of equity in respect of options exercise
17th Mar 20167:00 amRNSBoard Change
11th Mar 20164:36 pmRNSGrant of Options under Long Term Incentive Plan
8th Mar 20167:00 amRNSInterim Results for the six months ended 31/12/15
24th Feb 20167:30 amRNSHardman & Co Research Report: Development Progress
23rd Feb 20167:00 amRNSNotice of Interim Results
18th Feb 20167:00 amRNSPatient enrolment completed in US Phase IIb study
13th Jan 20167:00 amRNSTrading Update
7th Dec 20157:00 amRNSUS Phase II study for GrassMATAMPL initiated
2nd Dec 20153:47 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSPQBirch204 Phase II study update
27th Nov 20153:21 pmRNSHolding(s) in Company
25th Nov 20156:06 pmRNSGrant of Options under Long Term Incentive Plan
18th Nov 201512:23 pmRNSResult of AGM
17th Nov 201512:51 pmRNSResults of Placing
17th Nov 20157:01 amRNSProposed placing to raise up to £12 million
17th Nov 20157:00 amRNSTrading Update
4th Nov 20157:00 amRNSWorld Vaccine Congress Presentation
21st Oct 20152:48 pmRNSHardman & Co issues research report
16th Oct 20157:00 amRNSAnnual Report and Accounts
21st Sep 20157:00 amRNSFinal Results
1st Sep 20157:04 amRNSFirst patient recruited in PQ Birch dose study
10th Aug 20157:00 amRNSKey paper published in the World Allergy Journal
27th Jul 20157:00 amRNSDirector Share Dealings
23rd Jul 20157:00 amRNSNotice of Results and Trading Update
6th Jul 20157:00 amRNSPositive Dust Mite Study Results
2nd Jul 20157:00 amRNSCompany to Host Key Allergy Conference
25th Jun 20157:00 amRNSCompany to resume US clinical programme
5th Jun 201510:59 amRNSAcquisition of Alerpharma S.A.
9th Apr 20155:51 pmRNSHolding(s) in Company
8th Apr 20153:47 pmRNSHolding(s) in Company
1st Apr 20153:20 pmRNSHolding(s) in Company
30th Mar 201511:27 amRNSResult of General Meeting and Issue of Equity
10th Mar 20157:03 amRNSIssue of Equity
2nd Mar 20157:00 amRNSHalf Yearly Report
30th Jan 20153:58 pmRNSHolding(s) in Company
12th Jan 20157:00 amRNSTrading Update
16th Dec 20142:00 pmRNSChange of Adviser
19th Nov 20141:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.